Harbour Investments, Inc. Cellectar Biosciences, Inc. Transaction History

Harbour Investments, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.5 - $6.9 $1,400 - $2,760	-400 Closed	0 $0
Q4 2021 Feb 16, 2022	SELL	$6.1 - $10.2 $106,750 - $178,500	-17,500 Reduced 97.77%	400 $0
Q3 2021 Nov 15, 2021	BUY	$8.2 - $12.4 $82,000 - $124,000	10,000 Added 126.58%	17,900 $17,000
Q2 2021 Aug 16, 2021	BUY	$11.8 - $18.2 $11,800 - $18,200	1,000 Added 14.49%	7,900 $9,000
Q1 2021 Aug 17, 2021	BUY	$15.2 - $25.0 $98,800 - $162,500	6,500 Added 1625.0%	6,900 $11,000
Q1 2021 May 12, 2021	BUY	$15.2 - $25.0 $6,080 - $10,000	400 New	400 $1,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $13M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Harbour Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbour Investments, Inc. with notifications on news.